Agustin Casimiro‐Garcia

Publications by Year

Research Areas

HIV/AIDS drug development and treatment, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, HIV Research and Treatment, Hormonal Regulation and Hypertension

Most-Cited Works

• → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)189 cited
• → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited
• → Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors(2018)74 cited
• → ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling(2014)60 cited
• → A versatile copper-catalyzed coupling reaction of pyridin-2(1H)-ones with aryl halides(2006)56 cited
• → Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ(2011)52 cited
• → Novel Modifications in the Alkenyldiarylmethane (ADAM) Series of Non-Nucleoside Reverse Transcriptase Inhibitors(1999)43 cited
• → PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease(2020)40 cited
• → The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor(2007)39 cited
• → New Alkenyldiarylmethanes with Enhanced Potencies as Anti-HIV Agents Which Act as Non-Nucleoside Reverse Transcriptase Inhibitors(1998)30 cited